Protara Therapeutics is trading at $4.30 (12.9%) up in pre-market, reversing several days of declines as broader market sentiment improves.

  • The jump appears more related to a recovery in risk appetite following the recent market selloff rather than company-specific developments.
  • There are currently no fresh earnings reports, regulatory updates, or news items linked to the move.